PSIP1 and neoplasm: Additionally, immunocompetent, patient-specific tumor- and non-tumor-microtissues will be generated and treated with allosteric integrase inhibitors (which target LEDGF/p75) as potential therapeutic agents to elucidate the effect of inhibited LEDGF/p75 towards cellular proliferation and migration.